

The District Health Board Chief Executive Officers met on 25 June 2007 to consider the National Service and Technology Review Advisory Committee's recommendations on the Positron Emission Tomography (PET) Scanning business case. The CEO Group decided:

- that the Business Case for public funding and provision of Positron Emission Tomography (PET) in New Zealand did not provide adequate justification of additional patient benefit for the additional costs, and that the Business Case be declined on this basis;
- that there may be benefit for some patients to receive PET overseas or privately in New Zealand, and that consistent criteria be developed for publicly funded access to PET provided in Australia or privately, to come to a subsequent CEO Group meeting for approval;
- if the situation regarding public funding and provision of PET changed, then the CEO Group would consider the impact of the new information on their decision;
- to thank the group for their work on the Business Case, noting that the work provided a valuable resource and a solid base for the decision.

Following the Chief Executive Officers' decision, the Ministry of Health has asked the New Zealand Cancer Treatment Working Party to review the indications for publicly funded PET Scanning (whether overseas or privately in New Zealand) at their 8 August 2007 meeting. The indications will be forwarded as a recommendation to the District Health Board Chief Executive Officers.